Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.93 |
| ▸ | MLNR | O43193 | 3/20 | 0.93 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.93 |
| ▸ | ALB | P02768 | 1/20 | 0.93 |
| ▸ | CNR1 | P21554 | 1/20 | 0.93 |
| ▸ | HTR2A | P28223 | 1/20 | 0.93 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.93 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.93 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.85 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.85 |
| ▸ | AR | P10275 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | DRD1 | P21728 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL7056963 | 1.00 | CYP3A4 (0.93) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL9487690 | 0.97 | CYP3A4 (0.94) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL10620022 | 0.97 | CYP3A4 (0.94) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL10620016 | 0.97 | CYP3A4 (0.94) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL153013 | 0.97 | CYP3A4 (0.94) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL11201590 | 0.97 | CYP3A4 (0.96) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL6395349 | 0.97 | CYP3A4 (0.96) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL11503675 | 0.97 | CYP3A4 (0.96) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL10900217 | 0.96 | CYP3A4 (0.95) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL9054352 | 0.96 | CYP3A4 (0.95) | CYP3A4KCNH2MLNRABCB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-114129527-A | Miniature tablet and preparation method and preparation thereof | 北京微智瑞医药科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-112912386-A | Cell penetrating peptide based on influenza virus M2 protein | 中国医学科学院基础医学研究所 | 2021-06-04 | — | — | CN | claimed |
| CN-104857515-B | Drug core composition for controlled release drug delivery and osmotic pump preparation containing the same | 中国科学院上海药物研究所 | 2020-01-10 | — | — | CN | claimed |
| US-5158779-A | Particles of hydrophobic or sparingly soluble substance | GERGELY GERHARD (AT) | 1992-10-27 | — | — | US | claimed |
| WO-2026041873-A1 | COMPOSITIONS FOR SYSTEMIC ADMINISTRATION | THE UNIVERSITY OF READING (GB) | 2026-02-26 | — | — | WO | disclosed |
| EP-4629991-A1 | DELAYED RELEASE COMPOSITION WITH RESISTANCE AGAINST FED STATE GASTRIC CONDITIONS | Evonik Operations GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| CN-119136833-A | Membrane translocation domain and uses thereof | 俄亥俄州创新基金会 | 2024-12-13 | — | — | CN | disclosed |
| CN-118251211-A | Composition and method for producing the same | 维特斯集团 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024120944-A1 | DELAYED RELEASE COMPOSITION WITH RESISTANCE AGAINST FED STATE GASTRIC CONDITIONS | EVONIK OPERATIONS GMBH (DE) | 2024-06-13 | — | — | WO | disclosed |
| CN-113939277-B | Formulations and methods for drug infusion into the bladder and treatment of bladder diseases | 特瑞纲制药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | disclosed |
| EP-1075837-B1 | Process for the preparation of aqueous formulations for ophthalmic use | S I F I SOCIETA IND FARMACEUTI (IT) | 2003-05-07 | — | — | EP | disclosed |
| US-6277829-B1 | DISSOLVING AZITHROMYCIN IN SOLUTION OF POLYBASIC PHOSPHATE AND CITRIC ACID; TREATMENT OF CONJUNCTIVITIS, KERATITIS AND BLEPHARITIS | S.I.F.I. SOCIETA INDUSTRIA FARMACEUTICA ITALIANA S.P.A. (IT) | 2001-08-21 | — | — | US | disclosed |
| EP-1075837-A2 | Process for the preparation of aqueous formulations for ophthalmic use | S.I.F.I. Società Industria Farmaceutica Italiana S.p.A. (IT) | 2001-02-14 | — | — | EP | disclosed |
| US-5158779-A | Particles of hydrophobic or sparingly soluble substance | GERGELY GERHARD (AT) | 1992-10-27 | — | — | US | disclosed |
| US-4832956-A | Disintegrating tablet and process for its preparation | GERGELY GERHARD (AT) | 1989-05-23 | — | — | US | disclosed |
| US-4794000-A | Coacervate-based oral delivery system for medically useful compositions | SYNTHETIC BLOOD CORPORATION (US) | 1988-12-27 | — | — | US | disclosed |
| US-4219641-A | Process for preparing erythromycin succinate | THE UPJOHN COMPANY (US) | 1980-08-26 | — | — | US | disclosed |